The effects of CA IX on tumor phenotype can be blunted either by the silencing/suppression of the CA IX expression, or by the small molecule inhibitors of the CA IX catalytic activity, or by the CA IX-specific antibodies as documented in a number of published studies and reviews [61–68]. The gene discussed is CA9; the disease is neoplasm.